Aurobindo Pharma Q1 Review - Significant Revenue Miss Due To U.S., Anti-Retrovirals: ICICI Direct
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
ICICI Direct Report
Aurobindo Pharmaceuticals Ltd.’s Q1 FY22 operational performance was below our estimates amid a decline across U.S. market and anti-retrovirals whereas profit after tax was in line with estimates amid higher-than-expected other income and a lower tax rate.
Aurobindo Pharma's revenues de-grew 3.8% YoY to Rs 5702 crore tracking a 13.7% YoY decline in U.S. business to Rs 2681 crore, partially offset by 19.7% YoY growth in Europe formulations to Rs 1582 crore and growth of 13.7% YoY in rest of world markets to Rs 329 crore.
On the other hand, ARV segment de-grew 30.3% YoY to Rs 296 crore while active pharma ingredient segment grew 4.1% YoY to Rs 811 crore.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.